Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Transgender Health topic
No spam. Unsubscribe anytime.
Utah House rejects second‑substitute to study care of transgender minors after heated debate on puberty blockers
Summary
Lawmakers on the Utah House floor narrowly considered a second substitute for House Bill 449, which would have authorized an expedited Department of Health study of diagnosis, treatment and care for transgender minors; the measure failed 17–55 amid concerns about puberty‑blocking drug Lupron and community controversy.
Representative Karen Dahl, sponsor of House Bill 449 (second substitute), told the House the measure was intended to expedite a literature review by a panel of unbiased researchers about the diagnosis, treatment and care of transgender minors and, if the Department of Health could use direct contracting, to return the study in a shorter timeframe.
Dahl acknowledged the bill had generated “a lot of concern and a lot of controversy” and said she had encountered resistance to earlier proposals that would have outright banned procedures for minors. She singled out the puberty‑blocking drug Lupron as a particular concern, saying she had come to believe ‘‘this particular drug and also just the whole idea of blocking puberty is actually very problematic’’ and that more data were needed to understand potential harms and benefits.
During floor debate, no substantive amendments were adopted on the chamber floor. Members asked procedural and clarifying questions, and the sponsor stressed the goal was to obtain research and recommendations back to the Legislature by November so lawmakers could make informed policy choices.
On final passage, the second substitute failed in a voice‑recorded vote with 17 representatives voting yes and 55 voting no. The measure was referred to staff for filing and will not proceed to the Senate in its substituted form.
Why it matters: Supporters framed the bill as a fact‑finding step to inform future policy; opponents argued that the sponsor’s concerns about Lupron and treatment approaches did not justify the substitute language or a new statutory study mechanism. The failure leaves policy on diagnosis and care of transgender minors unchanged by statute and signals substantial floor opposition to the sponsor’s approach.
What comes next: The bill was returned to staff for filing; proponents and opponents could pursue alternative legislation, committee studies, or interim work to address the underlying questions about clinical practice and oversight.
